window.pageData = {"stock":{"_id":3000000026076,"stockCode":"026076","masterFundShortName":"恒生前海港股通科技成长混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":26076,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"恒生前海港股通科技成长混合A","name":"恒生前海港股通科技成长混合型证券投资基金","pinyin":"hsqhggtkjczhhxzqtzjj","fundCollectionId":4000051280000,"followedNum":1,"setUpAssetScale":19532781.91,"setUpDate":"2026-01-26T16:00:00.000Z","setUpShares":19532781.91,"inceptionDate":"2026-01-29T16:00:00.000Z","fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"51280000","tickerId":51280000,"name":"恒生前海基金管理有限公司"},"managers":[{"name":"邢程","stockType":"fund_manager","stockCode":"db20850059","exchange":"fm","tickerId":2403225370}],"hotMetrics":{"fpr":{"stockId":3000000026076,"type":"fpr","f_cagr_p_r_fs_ssc":9258,"f_cagr_p_r_fs_ssrp":0.9352922112995571,"f_p_r_m1_ssc":9298,"f_p_r_m1_ssrp":0.717973539851565,"f_p_r_m3_ssc":9145,"f_p_r_m3_ssrp":0.7120516185476815},"fp":{"stockId":3000000026076,"type":"fp","last_data_date":"2026-06-17T16:00:00.000Z","f_cagr_p_r_fs":-0.06670000000000009,"f_p_r_m1":-0.030539108756622135,"f_p_r_m3":-0.02679874869655896,"f_i_d":"2026-01-29T16:00:00.000Z"},"f_nlacan":{"stockId":3000000026076,"type":"f_nlacan","f_nv_d":"2026-06-17T16:00:00.000Z","f_nv":0.9333,"f_nv_cr":0.004412397761515363},"f_as":{"stockId":3000000026076,"type":"f_as","f_tas":14598824.1408,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000026077,"name":"恒生前海港股通科技成长混合型证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"026077","tickerId":26077,"shortName":"恒生前海港股通科技成长混合C","currency":"CNY","__csrcFundId":16220,"exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"lastUpdated":"2026-02-09T07:58:17.802Z","inceptionDate":"2026-01-29T16:00:00.000Z","pinyin":"hsqhggtkjczhhxzqtzjj","fundCollectionId":4000051280000}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000001585,"holdings":310000,"marketCap":3626717,"netValueRatio":0.0487,"quarterlyChange":0.16534740545294513,"stock":{"stockCode":"01585","exchange":"hk","stockType":"company","tickerId":1585,"name":"雅迪控股"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000006821,"holdings":45100,"marketCap":3623715,"netValueRatio":0.0486,"quarterlyChange":0.2780898876404492,"stock":{"exchange":"hk","stockType":"company","stockCode":"06821","tickerId":6821,"name":"凯莱英"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000001801,"holdings":41500,"marketCap":3110941,"netValueRatio":0.0417,"quarterlyChange":0.11344262295081897,"stock":{"stockCode":"01801","exchange":"hk","stockType":"company","tickerId":1801,"name":"信达生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000002607,"holdings":303800,"marketCap":3098174,"netValueRatio":0.0416,"quarterlyChange":0.014520744630397653,"stock":{"stockCode":"02607","exchange":"hk","stockType":"company","tickerId":2607,"name":"上海医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000002196,"holdings":177000,"marketCap":3097512,"netValueRatio":0.0416,"quarterlyChange":0.013810741687979133,"stock":{"stockCode":"02196","exchange":"hk","stockType":"company","tickerId":2196,"name":"复星医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000002359,"holdings":29700,"marketCap":3081274,"netValueRatio":0.0413,"quarterlyChange":0.19047619047619047,"stock":{"stockCode":"02359","exchange":"hk","stockType":"company","tickerId":2359,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000001177,"holdings":585000,"marketCap":3042336,"netValueRatio":0.0408,"quarterlyChange":-0.04692556634304246,"stock":{"stockCode":"01177","exchange":"hk","stockType":"company","tickerId":1177,"name":"中国生物制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000001099,"holdings":167600,"marketCap":2989244,"netValueRatio":0.0401,"quarterlyChange":0.039094650205760306,"stock":{"stockCode":"01099","exchange":"hk","stockType":"company","tickerId":1099,"name":"国药控股"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000001513,"holdings":121900,"marketCap":2951258,"netValueRatio":0.0396,"quarterlyChange":-0.03856942496493676,"stock":{"stockCode":"01513","exchange":"hk","stockType":"company","tickerId":1513,"name":"丽珠医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000026076,"stockId":1000000000000992,"holdings":364000,"marketCap":2940753,"netValueRatio":0.0395,"quarterlyChange":-0.01187904967602571,"stock":{"stockCode":"00992","exchange":"hk","stockType":"company","tickerId":992,"name":"联想集团"}}]},"list":[{"_id":"69e8ecc41398d79843fea1d0","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000026076,"sao":"2026年一季度，港股市场延续整体缺乏催化，春节前后并未出现AI产业催化事件，恒生科技保持弱势。2月28日伊朗局势爆发以来，战事已经步入第四周，在霍尔木兹海峡持续“实质性”封锁的情况下，全球能源市场的冲击加剧，局势升级和能源危机也引发了金融市场动荡的加剧。对流动性敏感的港股负面反应更大，若美债利率和美元维持高位，难免仍会对港股流动性造成一定冲击。除此之外，油价维持高位也使得全球滞胀甚至衰退风险加剧，从而影响上市公司的盈利预期。在基金运作层面，我们于一季度逐步建仓完成并保持了较高仓位运行。　　展望2026年二季度，我们的基准假设是地缘冲突或不会延续至三四季度，下半年美联储依然有一定概率降息，则权益资产的下行压力也有望明显缓解。此外，在宏观缺乏强支撑和流动性充沛的大背景下，我们仍然维持港股以结构性为主的判断. 港股市场后续上行空间的打开或需要企业盈利的进一步修复，而非仅仅依靠估值和风险溢价的线性外扩。宏观方面，我们认为基准情形是此轮的AI科技浪潮尚未过热，正如中国经济构成中日趋重要的新质生产力，AI投资同样也带动了美国经济周期和信用周期的上行，因此AI科技叙事是中美市场上行的基础。因此，我们仍旧看好人工智能相关的成长主线，同时关注潜在需求冲击风险。　　目前港股市场估值水平的吸引力在逐步显现，中期来看市场或在波折中上行，国内稳增长政策变化以及美联储货币政策路径值得进一步跟踪。影响香港市场定价的分子端企业盈利和分母端流动性因子有望得到边际改善，相对较低估值水平不仅将为市场抵御外部波动提供缓冲，也有望使港股市场对潜在的增长修复和政策信号更为敏感，从而提供更大的弹性。我们将关注成长板块中盈利改善、对流动性敏感型行业，如科技成长板块中的互联网、科技硬件、医疗保健等行业。","lastUpdated":"2026-04-22T15:44:04.237Z","fund":{"_id":3000000026076,"__csrcFundId":16220,"stockCode":"026076","masterFundShortName":"恒生前海港股通科技成长混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":26076,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"恒生前海港股通科技成长混合(026076)","lastUpdated":"2026-05-01T05:01:37.999Z","name":"恒生前海港股通科技成长混合型证券投资基金","pinyin":"hsqhggtkjczhhxzqtzjj","fundCollectionId":4000051280000,"followedNum":1,"setUpAssetScale":19532781.91,"setUpDate":"2026-01-26T16:00:00.000Z","setUpShares":19532781.91,"inceptionDate":"2026-01-29T16:00:00.000Z","managers":[{"stockCode":"db20850059","stockType":"fund_manager","exchange":"fm","tickerId":2403225370,"name":"邢程"}]},"announcement":{"linkText":"恒生前海港股通科技成长混合型证券投资基金2026年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1474012","linkType":"PDF","source":"csrc_pdf"}}]}